glp 1 oral drops side effects How to take GLP-1 drops: complete step by step administration guide The new generation of weight

The benefits extend beyond mere weight reduction

Health Canada approves Victoza as the first and only GLP-1 receptor agonist to reduce the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease

For more patient education, you can also read our blog articles on diabetes and weight management

In the Liraglutide Effects in Atrial Fibrillation (LEAF) Study, researchers at the University of Miami Miller School of Medicine, led by Jeffrey Goldberger, M.D., cardiac electrophysiologist and professor of cardiovascular medicine at the Miller School, found that adding the GLP1 receptor agonist liraglutide to a structured riskfactor modification program significantly improved freedom from AFib or atrial flutter one year after catheter ablation in overweight and obese patients

No, GLP-1 therapy is not recommended during pregnancy or if you are trying to conceive